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Abstract
Background: This study aims to calculate the health effects and costs of a proposed national
hypertension prevention and control program.
Methods: Interventions are based on experience from our two programs: 10-year period of
Ashkelon Hypertension Detection and Control Program (AHDC Program) and the Israel Blood
Pressure Control (IBPC) program. The costs of a nationwide program were calculated based on
economic data, training staff levels, course frequency and unit costs.
Results: Over the next 20 years, the program should decrease the risk in one-half of the treated
hypertensive cases of the following ailments: cardiovascular events such as Acute Myocardial
Infarction (AMI) and Unstable Angina Pectoris (UAP) by 16.0%, stroke by 41.2%, End stage renal
disease (ESRD) by 50.0% and peripheral vascular disease (PVD) by 42.6%. In total, around 2,242
lives, 35,117 years of life or 24,433 disability adjusted life years will be saved due to decreased
mortality.
Program costs amount to $352.7 million. However savings ($537.6 million), from reduced medical
treatment ($444.3 million) and reduced pharmaceutical use ($93.3 million) as a result of morbidity
decreases, exceed costs by $185.0 million.
Conclusion: The project which saves both lives and resources should be extended nation-wide
to reach as wide a population as possible.
Background
Cardiovascular (CV) risk factors such as hypertension,
hyperlipidemia and diabetes, are insufficiently managed,
according to current guidelines [1]. This mismanagement
occurs in spite of the accepted fact that reaching the rec-
ommended target goals of the various guidelines is an
effective means to reduce morbidity and mortality from
atherosclerosis and vascular events [2,3]. Reasons for this
shortfall have been described in many recent studies,
showing that both the American [4,5] and the European
[6,7] guidelines, are not truly implemented.
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As in other developed nations, the burden of disease
attributable to Hypertension, heart disease and stroke in
Israel is considerable. These diseases are also among the
most expensive diseases to treat [8]. In response to these
important issues of disease burden in terms of human suf-
fering and treatment cost, we initiated the Ashkelon
Hypertension Detection and Control Program (AHDC
Program): a community approach to reducing cardiovas-
cular mortality [9]. During a 10-year period (1980–1990),
we operated a professional doctor-nurse screening team,
who were instructed to find those at high risk in control of
their risk factors, in order to reduce CV morbidity and
mortality. They examined 12,202 subjects, (mean age 51
+/- 7 years, range 20–65 years) accounting for 23.4% of
the total regional population. High risk subjects under-
went an intensive CV risk factor control program. Subjects
(3,506 or 28.6%) were found to have one or more CV risk
factors (hypertension, obesity, smoking, hypercholestero-
lemia). During an average of 2 years, follow-up BP, weight
reduction, and smoking cessation remained statistically
significant. Total cholesterol was unchanged. Over this
period, the standardized mortality ratio (SMR) in the area
for acute MI fell from 100 to 76 (P < 0.01), for CV disease
from 129 to 107 (P < 0.0001), and for hypertension from
121 to 87 (P < 0.1 NS). The project saved many life-years
at no additional net cost to society, and cost-effectiveness
analysis showed positive results. Our community
approach with mainly non pharmacological treatment
was proven to be feasible and cost-effective in reducing CV
morbidity and mortality. Subsequent we conducted the
Israel Blood Pressure Control (IBPC) program [10], in the
year 2000 in 30 general practice clinics in Israel. After 1
year of intervention in 4848 patients according to our
method [10], there was a significant increase in control of
risk factors. In hypertension this percentage raised from
29.0 to 46.7%, in control of body weight from 36.7 to
43.8%, in Low Density Lipoprotein (LDL) levels from
31.2 to 41.7% while the percentage of patients with glu-
cose levels above 200 mg/dl dropped from 5.2 to 3.1%.
Encouraged by these results we decided to propose a
nationwide program that could also be extended to act in
cooperation with neighboring countries. This study was
initiated to help attain this goal and convince the health
authorities, by presenting the costs and the utilities if the
Ashkelon project were to be extended nationwide.
Methods
Interventions will be based on experience from the fol-
lowing two programs:
Ashkelon Hypertension Detection and Control Program 
(AHDC Program)
During a 10-year period (1980–1990 screening team,
(MD and RN) acted to detect those at high risk to develop
CV disease in order to reduce CV morbidity and mortality.
They examined 12,202 subjects, (mean age 51 +/- 7 years,
range 20–65 years) accounting for 23.4% of the total
regional population. High risk subjects underwent an
intensive CV risk factor control program [9].
Israel Blood Pressure Control (IBPC) program
The IBPC program was initiated in the year 2000. in this
survey, we included patients from 30 general practice clin-
ics across Israel, directed by specialists in family medicine,
each seeing 1000–5000 patients. The authors presented
the program to all available general practice clinics in
Israel. Those physicians who showed readiness to join the
program were enrolled on the study [10].
Costs of program
The costs of a nationwide program to reduce hypertension
in Israelis aged 25–64 years old were calculated based on
economic data, training staff levels, course frequency and
unit costs (Appendix I). All costs are presented at April
2005 price levels using a 3% discount rate for the period
2005–2024. The staff education costs included educating
two members of staff from each ambulatory clinic, opera-
tional costs (including tele-medicine) as well as two half-
days a year of courses to maintain the level of staff educa-
tion. Additional treatment costs of patients were calcu-
lated for the estimated 320,516 hypertensive cases [11,12]
aged 25–64 living in Israel not only for the initial year,
based on $230 per hypertensive cases less the costs of cur-
rent existing utilization of 4 visits per year by 25% of all
hypertensive cases. The costs of maintenance therapy were
added, amounting to a discounted sum of $208 per
treated person. The program will incur extra drug costs as
50% of hypertensive cases will be prescribed the correct
preventive regimen of Ace Inhibitor, Aspirin and Satins
costing around $0.92 per day. The remaining 50% would
be treated by non-pharmacological methods.
Incidence and mortality reductions
Disease treatment costs, both in the presence and absence
of the intervention program were based on spreadsheet
modeling combining unit treatment costs (Appendix I),
epidemiological (Appendix II), treatment efficacy
(Appendix II) and demographic factors (Appendix III).
Similarly Disability Adjusted Life Years (DALY) lost from
morbidity and mortality of diseases in the presence and
absence of the program were calculated using the data
contained in appendices II and III. All costs and utilities
used a 3% discount rate for the period 2005–2024.
Based on previous experience [9,10,13], it was assumed
that 50% of the persons participating would be success-
fully treated. Using a spreadsheet, the program benefits
were estimated in terms of incidence and mortality reduc-
tions in hypertensive cases [2] over the period 2005–2024Cost Effectiveness and Resource Allocation 2007, 5:16 http://www.resource-allocation.com/content/5/1/16
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(see Table 1) by gender and age group [25-44, 45-54, 55-
64], as follows:
AMI & UAP
Incidence data was based on national survey data [14], 20
year age-specific AMI and UAP risks [11] were conserva-
tively assumed to increase gradually by 1% annually to
reflect an increase in other risk factors (eg: obesity). A 16%
decrease in relative risk of AMI and UAP was assumed to
occur in those 50% who were successfully treated, based
on Israeli results [9,10] that corroborated international
findings [15-17]. One year post-AMI or Post-UAP case
fatality rates [18] were adjusted by age and gender specific
national background mortality rates to estimate the one
year post-AMI excess mortality rates.
CVA
Incidence data and 20 year age-specific risks were based
on Tel-Aviv stroke registry data [19]. The 1.7 relative risk
of strokes in hypertensive cases [19] translates into a
potential 41.2% reduction (1–1.0/1.7) of strokes in suc-
cessfully treated hypertensive cases. As one year post-hos-
pitalization mortality rates were not available, in-hospital
mortality rates were used to estimate excess mortality [19].
ESRD
National age and gender specific incidence rates of dialy-
sis patients and post renal transplants were obtained [20].
The relative risks (of 2.00) of ESRD in hypertensive cases
(with blood pressure >140/>90) and persons with high
normal blood pressure (with blood pressure of 130 to
139/85 to 89 mmHg.) compared to persons with blood
pressure <130/85 were based on a recent study of 316,675
adults [21]. Incidence and relative risks were used to cal-
culate 20 year age-specific risks for hypertensive cases.
Under the assumption that 25% of hypertensive became
normotensive cases and 25% became controlled (9,10),
as defined to be below 140/90 mmHg according to the
JNC VII guidelines [22], then the project will reduce ESRD
by around 25.0%. One year ESRD mortality rates were
used to attribute mortality due to hypertension [20].
PVD
Twenty year PVD risks were calculated by adjusting the age
and gender specific 20 year CVA risks by the relative inci-
dence of PVD to CVA [23]. Two groups of 25% of treated
hypertensive cases were assumed to become normoten-
sive cases and controlled hypertensive cases with a risk
reduction of 56.8% and 28.4% respectively for PVD [23].
No excess mortality was attributed to PVD.
Impact on treatment costs
Disease, age and gender specific decreases in incidence
due to the program were multiplied by the average disease
specific treatment costs obtained either from patient sur-
veys [14], the Ministry of Health's official price list or from
the accounts department of the Barzilai Medical Center.
(Appendix I) and the standard protocols for hospital and
post-hospital treatment (Appendix III).
AMI & UAP: AMI & UAP
National survey data was obtained on disease specific
treatment interventions [14]. Costs were based on the
budget backed-up assumption (of the Medical Technol-
ogy Assessment Division of the Ministry of Health) that
Cyphers would account for 40% of all simple stent and
Cypher usage in the future.
CVA
Based on experience in Barzilai Medical Center, after 8
days average length of stay, 20% of stoke patients are dis-
charged for three months average stay in a rehabilitation
facility, after which they receive 3 months physiotherapy
in a home setting. The remaining 80% of patients are dis-
charged straight to three months physiotherapy in a home
setting. Post hospitalization drug usage was assumed to be
as for AMI.
ESRD
Currently 5.9% of ESRD patients have received trans-
plants [20] and the rest are on dialysis (88% on haemodi-
alysis, 12% on Peritoneal dialysis) for an average of 5.05
years [20]. Time on dialysis fell with age from 9.70 years
(under 44 years) and 6.11 years (45–64) to 3.59 years
(65+).
PVD
Treatment costs were based on an estimated of 3.5 outpa-
tient visits a year over 10 years for treatment of PVD, based
Table 1: Key Epidemiologic Variables. [Acute Myocardial Infarctions (AMI), Cerebrovascular Accident (CVA), End Stage Renal 
Disease (ESRD) and M/F = Male/Female].
Age/Sex Hypertension (%) AMI (20 y %risk) CVA (rate/1000) ESRD (rate/100,000)
25–44 M/F 3.8/3.2 5–22 1.14 NA
45–54 M/F 14.7/13.9 23–32 2.28 31.9/16.7
55–64 M/F 34.5/27.8 33–50 5.11 77.8/44.6
65< 50< 50< 9.86 148.7/88.5Cost Effectiveness and Resource Allocation 2007, 5:16 http://www.resource-allocation.com/content/5/1/16
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on current Israeli protocols and practice for monitoring
PVD patients for any deterioration, every 3 to 4 months.
Disability Adjusted Life Year (DALYs) saved
DALY gains (subject to a 3% discount rate) were calcu-
lated by aggregating the gains from decreased mortality
and morbidity as a result of the program's intervention.
The average health state valuation (HSV) is less than one,
especially in older age groups where people have multiple
dysfunctions. In order to reflect this, DALYs saved from
averted deaths were calculated by multiplying the disease
specific life year gains by the age and gender specific
healthy adjusted life expectancies (HALE) [24].
Age-specific HSVs for disease conditions were obtained
from the WHO global burden of disease study [25]. Total
DALYs loss from morbidity was obtained by multiplying
age-specific disease incidence by the average disability loss
(1-HSV) and by the time spent in the morbid condition,
obtained from the WHO [26] or from the survey of dialy-
sis patients for ESRD [19]. For PVD disease duration was
assumed to be for 10 years with a HSV of 0.975 (or disa-
bility weight of 0.025).
Cost per DALYs ratio
The net cost of the program was calculated by subtracting
the reduced treatment costs (including reduced use of
pharmaceuticals) from the running cost of the program.
The major cost-effectiveness indicator is the Cost per
DALYs ratio calculated by dividing the net cost of the
project by the expected number of DALYs saved. This was
only able to be calculated where the project was not cost-
saving.
Projects are considered to be cost saving if their net cost is
negative, very cost-effective if the cost per DALYs is less
than the gross domestic product (GDP) per capita, cost-
effective if the cost per DALY is between one and three
times the GDP per capita and not cost-effective if the cost
per DALYs exceeds three times the per capita GDP [27].
Results
The program is expected to result in their being 8,749
fewer AMIs, 8,134 fewer PVDs, 8,074 fewer CVAs, 6,765
fewer UAPs and 2,316 fewer cases of ESRD (Table 2).
Around half of the estimated total of 2,242 fewer deaths
will be due to the reduction in cerebrovascular strokes
(1,114 fewer deaths), while there will be 543 fewer deaths
from AMIs, 440 fewer deaths from ESRD and 145 fewer
deaths from UAP (Table 2). These translate into a total of
35,117 life years saved, around 48.1% due to decreased
CVA (Table 3). After adjusting for disabilities, around
18,726 discounted DALYs (24,433 undiscounted) are
saved from reduced mortality, of whom 48.6% are due to
reduced CVA, 24.6% from fewer AMIs, 20.6% from
reduced ESRD and 6.3% from reduced UAP (Table 3).
A smaller quantity of DALYs (13,643 discounted and
17,801 undiscounted) will be saved from reduced mor-
bidity. While the large majority of morbidity gains
(around 61.5%) are due to decreased CVA incidence,
AMI/UAP and ESRD account for a further 14.3% and
14.3% respectively (Table 3).
In total, around 32,369 discounted DALYs will be saved,
around 57.9% being attributable to reduced CVA mortal-
ity. Program costs amount to $352.7 million, including
$9.8 million for staff education, $19.2 million for tele-
medicine and operational expenses, $70.0 million for
patient training during the first year of treatment, $66.8
for patient maintenance visits in subsequent years and
$186.2 million for additional use of pharmaceuticals.
Averted renal dialysis and transplants accounted for the
majority (70.2%) of the $ 444.4 million savings in
reduced medical treatment costs. In addition there were
$93.3 million savings from reduced pharmaceutical use as
a result of morbidity decreases. Thus the total of treatment
and drug savings ($537.7 million) exceeds treatment costs
by $185.0 million (Table 4).
Table 2: Impact of Hypertension Control Program on incidence and mortality (2005–2024). [Acute Myocardial Infarctions (AMI), 
Unstable Angina Pectoris (UAP), Cerebrovascular Accident (CVA), End Stage Renal Disease (ESRD) and Peripheral Vascular Disease 
(PVD)].
INCIDENCE 
Without Program
INCIDENCE 
With Program
Decrease MORTALTY 
Without Program
MORTALITY 
With Program
Decrease
AMI 98,182 89,433 8,749 6,094 5,551 543
UAP 38,939 32,174 6,765 696 552 145
CVA 39,217 31,143 8,074 5,412 4,298 1,114
ESRD 9,277 6,961 2,316 1,763 1,323 440
PVD 38,194 30,060 8,134 NA NA NA
TOTAL NA NA NA 13,965 11,723 2,242Cost Effectiveness and Resource Allocation 2007, 5:16 http://www.resource-allocation.com/content/5/1/16
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Sensitivity analyses
Sensitivity analyses are reported on the parameters that
were thought ex-ante to have the most potential to influ-
ence the costs and utilities.
Using no discount rate, decreasing the attainable risk
reduction for each disease by 30%, or decreasing the per-
centage of persons successfully treated from 50% to 40%,
all resulted in the project still being cost-saving. Even if
the overall attained decrease in hypertension were to fall
by half to 12.5%, the project would still be cost saving
(saving $29 million) in addition to saving 28,052 DALYs.
The cost-effectiveness indicators were particularly sensi-
tive to the number of years people received dialysis. If the
average number of years were to drop from 5 to 4 years
then total DALYs would be 32,212 and cost savings would
fall to $123 million. If time on dialysis would increase to
six years, then DALYs saved would rise to 32,565 and cost-
savings rise to $247 million.
Discussion
Coronary heart disease and Cerebrovascular Accident
(CVA) prevention are priority areas for improving health,
especially in developed nations. World-wide targets have
been set for the reducing the major Cardiovascular (CV)
risk factors: Blood Pressure (BP), diabetes, dyslipidemia,
smoking and diet in relation to obesity [28,29]. Nation-
wide projects are called for in order to significantly shift
any nation's risk factor profile towards proven goals.
Health policy and economic decisions makers in each
country will be more likely to accept such large preventive
projects not only if it the project is proven to save lifes and
reduce morbidity, but also if it cost-effective (ie: having a
low or even negative cost-per DALYs).
Our calculations show that implementation of a nation-
wide program to reduce hypertension, is likely to save
over two thousand lives in the next 20 years, improve the
quality of life in many more people and at the same time
actually save $185.0 million in health care resources
alone. The study is limited in the sense that it is using cur-
rent estimates of relative risk and demographics to project
disease incidence many years into the future. Economic
changes over the next two decades are likely to influence
the cost-utility ratio in so far as they will affect lifestyles
(eg: may be increased obesity) which in turn will increase
or decrease incidence of the diseases in question. In addi-
tion biases exist which tend to underestimate DALYs ben-
efits as follows:-
a) Because mortality was only attributable for AMI and
UAP for a one year post-hospitalization period. Deaths
after this timeframe were conservatively not attributed to
coronary syndromes. Similarly deaths due to stroke were
very conservatively estimated because stroke deaths were
only attributed to in-hospital mortality.
b) We based life years gained on the age specific life
expectancies, unadjusted for a decrease of the disease in
question. For example, if the program eradicates x% of
AMIs, then life years saved should be based on a life
expectancies adjusted upwards because of the eradication
of x% of deaths from AMIs.
c) our model based its duration of ESRD solely on data
from patients receiving dialysis. It is likely that this under-
estimates the true amount of life years saved as it excludes
data from patients who had undergone transplants and
had not reverted to dialysis [20]. DALYs benefits will be
over or underestimated to the extent that fewer or more
coronary events occur in February and March, the months
on which the incidence survey was based [14]. The ques-
tion whether there is a need for such a nationwide pro-
gram is clear form many studies [2-5] which prove the
need for risk factor control in order to achieve CV disease
prevention. Despite this, there is growing evidence that
the guidelines are not implemented enough and there is
under treatment [5-7], poor patient compliance, physi-
cian's unawareness of the new recommendations [19],
and non adherence to updating treatment and to targets of
treatments [20,21].
Table 4: National Program Resource Costs and Savings:
Training Staff $29,679,980
Training Hypertensive cases $70,037,048
Maintenance Visits $66,797,601
Extra Drug Costs $186,182,588
TOTAL PROGRAM COSTS $352,697,217
Reduced Treatment $444,382,484
Reduced drug Use $93,270,706
TOTAL SAVINGS $537,653,190
NET PROGRAM SAVINGS $184,955,973
Table 3: Life years and discounted DALYs saved (2005-2024) of 
hypertension program. [Acute Myocardial Infarctions (AMI), 
Unstable Angina Pectoris (UAP), Cerebrovascular Accident 
(CVA), End Stage Renal Disease (ESRD) and Peripheral Vascular 
Disease (PVD), Disability Adjusted Life Years (DALYs)].
Mortality Morbidity Total
Life Years DALY DALY DALY
AMI 8,925 4,611 159 4,770
UAP 2,401 1,174 330 1,504
CVA 16,904 9,091 10,812 19,903
ESRD 6,888 3,850 783 4,633
PVD - - 1,558 1,558
TOTAL 35,117 18,726 13,643 32,369Cost Effectiveness and Resource Allocation 2007, 5:16 http://www.resource-allocation.com/content/5/1/16
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Economic-Epidemiologic analysis has become a standard
method for informing health policy makers, and is also
helpful for individual physicians making medical deci-
sions [28]. For each of the various CV risk factors, espe-
cially hypertension on account of the high prevalence,
and the need for long-term, perhaps lifelong, treatment,
quite minor changes in antihypertensive practices can
have a significant impact on healthcare budgets [29].
Our first previous study, the Ashkelon Hypertension
Detection and Control Program (AHDC Program),
showed that a community approach to reduce cardiovas-
cular mortality [9], during a 10-year period (1980–1990),
can affect reduce CV morbidity and mortality. During an
average of 6.4 years, follow-up BP, weight reduction, and
smoking cessation, the standardized mortality ratio SMRs
for MI, CVD and hypertensive diseases fell significantly.
The project saved many life-years at no additional net cost
to society. Also in our second project: the Israel Blood
Pressure Control (IBPC) program [10], there was a signif-
icant increase in the percentage of patents defined as "con-
trolled" in hypertension, Low Density Lipoprotein (LDL)
levels and in the percentage of patients with diabetes.
It is important to note the impact of decreased mortality
by estimating the additional Disability Adjusted Years of
Life (DALYs) and not only life years added.
Each hypertension related disease encounters many meas-
urable obstacles which patients face during their rehabili-
tation, which in many cases are not completely resolved.
These diseases can cause pain, suffering, increasing dys-
function, temporary or permanent unemployment
accompanied by attendant life stresses and major reduc-
tions in self image and in family status. In Israel, AMI
patients are automatically absent from work for three
months of rehabilitation as the minimum even if there are
no AMI complications. This example shows that on top of
the treatment and secondary prevention cost of each AMI
there is also a considerable socioeconomic burden that
may influence the total balance of the cost utility analysis.
Although probably underestimated the program is
expected to result in 8,749 fewer AMIs, 8,134 fewer PVDs,
8,074 fewer CVAs, 6,765 fewer UAPs and 2,316 fewer
cases of ESRD (Table 2). Around half of the estimated
total of 2,242 fewer deaths will be due to the reduction in
cerebrovascular strokes (1,114 fewer deaths), while there
will be 543 fewer deaths from AMIs, 440 fewer deaths
from ESRD and 145 fewer deaths from UAP. These trans-
lates into a total of 35,117 life years saved.
For CVA the whole socioeconomic benefits are even more
likely to have been underestimated, as the program may
also prevent work disability. The 1.7 relative risk of strokes
in hypertensive patients [19] translates into a potential
41.2% reduction of strokes and stroke sequlae in success-
fully treated hypertensive cases. A further source of under-
estimation of DALYs saved is that our model based its
duration of ESRD solely on data from patients receiving
dialysis. It is likely that this underestimates the true
amount of life years saved as it excludes data from patients
who had undergone transplants and had not reverted to
dialysis [20].
We feel that, consideration should be given to extending
such a potentially cost-effective project (which saves life
years, morbidity and resources) to a nationwide basis, in
order to encompass as many people as possible.
Conclusion
Our study shows that a national health education pro-
gram to reduce cardiovascular risk factors, over the next 20
years, should succeed in decreasing the risk in one-half of
AMI and UAP by 16.0%, CVA by 41.2%, CRF by 50.0%
and PVD by 42.6%. The implementation of such a pro-
gram nationwide is likely to save over two thousand lives,
improve the quality of life in many more people and at
the same time actually save $185.0 million in health care
resources alone. It is conceivable that it may be extended
not only throughout our country, but also to neighboring
countries.
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Table 5: 
Appendix I: Key Economic Variables Reference/Data Source
ECONOMIC
Annual Discount Rate 3% 27
Exchange Rate: Shekels to USD (2005) 4.35 12
Per capita GDP (USD 2003) $16,497 12
Training Staff
Number of Clinics in Israel 3000 MOH Statistical Dept.
Staff per clinic receiving training 2 Ashkelon Project
Full Days Training in initial year 2 Ashkelon Project
Days training in subsequent years 1 Ashkelon Project
Cost per ticipant-day of training course $100 Ashkelon Project
Tele-management & Operational costs per patient. $60 Ashkelon Project
Nurse/GP guidance per patient in first year of program $230 Ashkelon Project
Unit Care Costs
Ambulatory visit to Nurse or Nutritionist $7.83 15 mins visit & 5 mins secretarial time
Ambulatory GP visit $11.37 15 mins GP & 5 mins secretarial time
Cost of OPV $99.14 25% of general hospital cost (30)
General Hospital Cost per day $397 30
ICU cost per day $1,586 estimated as four times general per diem cost (30)
Rehabilitation Hospital Cost per day $238.85 30
Home Physiotherapy Visit $38.53 30
Devices and Procedure costs
Stent $202 Barzelai Hospital Accounts Dept.
Cypher $2,989 Barzelai Hospital Accounts Dept.
Diagnostic Catheterisation $2,464 30
Restenosis $9,701 30, includes 1 day in ICU & 3 days in cardiac ward
Average cost of Catheterisation with Stent or cypher $6,925 30
CABG operation $12,740 30
TPA $1,800 30 estimated as four times general per diem cost
PRS Streptokinaise $81 31
Kidney Transplant Cost $39,132 30
Haemodialysis cost $313 30
Peritonea dialysis cost $136 30
% receiving haemodialysis 88.8% 20
Average annual Dialysis Cost $46,041 30
Drug Costs
Post-MI or stroke drugs per day per patient- Males $1.92 14
Post-MI or stroke drugs per day per patient- Females $1.79 14
Post-UAP drugs per day per patient- Males $1.92 14
Post-UAP drugs per day per patient- Females $1.79 14
Correct preventive medication per day $0.92 14, Ace inhibitor, Aspirin & Statin
Inadequate preventive medication per day $0.31 14, Assumed only 1 correct drug takenCost Effectiveness and Resource Allocation 2007, 5:16 http://www.resource-allocation.com/content/5/1/16
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Table 6: 
Appendix II: Key Epidemiologic Variables Reference/Data Source
EPIDEMIOLOGIC
Male life expectancy at age 60 (years) 20.9 12
Female life expectancy at age 60 (years) 23.4 12
Healthy Adjusted Life expectancy at age 60 males 16.8 24
Healthy Adjusted Life expectancy at age 60 females 18.2 24
Hypertension
% hypertensive cases, Males 25–44 3.8% 12
% hypertensive cases, Males 45–54 14.7% 12
% hypertensive cases, Males 55–64 27.8% 12
% hypertensive cases, Females 25–44 3.2% 12
% hypertensive cases, Females 45–54 13.9% 12
% hypertensive cases, Females 55–64 34.5% 12
% of persons treated successfully in program 50% 9,10,13
Acute MI
Annual Incidence 8940 14
% AMI in Males 77.0% 14
20 year MI risk at age 25 5.0% 11
20 year MI risk at age 30 7.5% 11
20 year MI risk at age 35 10.0% 11
20 year MI risk at age 40 16.0% 11
20 year MI risk at age 45 22.0% 11
20 year MI risk at age 50 27.0% 11
20 year MI risk at age 55 32.0% 11
20 year MI risk at age 60 41.0% 11
20 year MI risk at age 65 50.0% 11
Annual increase in MI risk over 20 years 1.0% Assumed
Decrease in risk of MI in persons successfully treated 16.0% 9,10,15–17
Health Status Valuation of MI patient 0.61 25
Years in decreased health state. 0.06 26
Unstable Angina Pectoris
Annual Incidence 3354 14
% UAP in males 73.9% 14
Decrease in risk of UAP in persons succesfully treated 16.0% 9,10,15–17
Health Status Valuation of UAP patient 0.91 25
Years in decreased health state. 1.00 26
Stroke
Mean age of stroke 73.2 19
% strokes in males 58.2% 19
Relative Risk of Stroke in Hypertensive cases 1.7 19
Stroke rate per 1000 aged 45–55 1.14 19
Stroke rate per 1000 aged 55–64 2.28 19
Stroke rate per 1000 aged 65–74 5.11 19
Stroke rate per 1000 aged 75–84 9.86 19
Decrease in Stroke risk in persons successfully treated 41.2% 19
Health Status Valuation of first ever stroke patient 0.78 25
Years in decreased health state. 7.80 26
Chronic Renal Failure
ESRD incidence rates per 100,000 Males 45–54 31.9 19
ESRD incidence rates per 100,000 Males 55–64 77.8 19
ESRD incidence rates per 100,000 Males 65–74 148.7 19
ESRD incidence rates per 100,000 Males 75+ 174.2 19
ESRD incidence rates per 100,000 Females 45–54 16.7 19
ESRD incidence rates per 100,000 Females 55–64 44.6 19
ESRD incidence rates per 100,000 Females 65–74 88.5 19Cost Effectiveness and Resource Allocation 2007, 5:16 http://www.resource-allocation.com/content/5/1/16
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Table 7: 
Appendix III: Key Utilization variables. Reference/Data Source
UTILIZATION Both Genders
Hypertension Treatment
% of persons transferred to NPC of hypertension 50% 9
Existing ambulatory visits in first year for hypertension 1.0 Barzelai Hospital
Existing annual maintenance visits for hypertension 0.5 Barzelai Hospital
Annual maintenance visits in program 2.0 9
Average time of visit (minutes) 15 9
Males Females
AMI Treatment
GP visits in three years prior to AMI 10 10 Assumption
% AMI that are catheterised 72% 59% 14
% AMI getting stent/baloon (primary PCI) 19% 14% 14
% AMI getting stent (late PCI) 38% 32% 14
% AMI getting CABG 8% 4% 14
% AMI being discharged after catheterisation 7% 9% 14
% AMI being discharged with no catheterisation 5% 22% 14
% AMI with Thrombolysis 23% 19% 14
% AMI rehospitalised for cardiac reasons in month 15.4% 15.7% 14
% ratio of cyphers to all cypher-stent usage 40.0% 40.0% MOH Medical Technology 
Assesment Dept.
ESRD incidence rates per 100,000 Females 75+ 71.9 19
Decrease in ESRD risk in persons successfully treated 49.9% 10
Health Status Valuation of ESRD 0.904 28
PVD
PVD incidence per 1000 male hypertensive cases 6.20 23
PVD incidence per 1000 female hypertensive cases 3.65 23
PVD Relative Risk in Hypertensive to Normotensive cases 2.31 23
PVD Relative Risk in Hypertensive to controlled cases 1.40 23
Attainable risk reduction Hypertensive to Normotensive cases 56.8% 23
Attainable risk reduction Hypertensive to Controlled cases 28.4% 23
% treated who become controlled cases 50% 9,10
% treated who become normotensive cases 50% 9,10
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